BPC-157 and TB-500: why these two are often discussed together
The short version: two peptides studied in tissue-repair research that appear to act on different parts of the same biology — and both are awaiting a final FDA decision.
TL;DR
- BPC-157 and TB-500 (thymosin beta-4) are both studied in tissue-repair research, in different but complementary ways.
- Most published evidence is preclinical (animal and cell models). Direct human trial data on either is limited.
- Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
What it is
BPC-157 (in plain English: body protection compound 157 — a 15-amino-acid sequence first identified in human gastric juice) and TB-500 (in plain English: a synthetic fragment derived from the protein thymosin beta-4) are two of the most-discussed peptides in the tissue-repair literature. They are routinely paired in podcasts and online forums, but the underlying reason is biology: each compound appears to act on a different lever of the wound-healing pathway, in animal studies (Sikiric et al., Curr Pharm Des, 2014).
How it works
Think of injured tissue as a construction site. TB-500 behaves like the safety crew that signals workers where to move — it influences cell migration and the actin cytoskeleton (in plain English: the internal scaffolding that lets cells crawl and shape-change). BPC-157 behaves like the on-site engineer who grows new water lines — it has been shown to influence angiogenesis (in plain English: the formation of new blood vessels) and growth-factor signaling (Goldstein et al., FEBS J, 2012). Different jobs, same site, partly overlapping outcomes in the animal data.
Who asks about it
People come to this topic after hearing the pair discussed in recovery podcasts. They want to understand whether the combination has clinical evidence behind it. The honest answer is: the rationale is mechanistic and animal-based; the human data is limited; FDA has not yet made a final decision on either peptide.
What the research says
A Current Pharmaceutical Design review summarized BPC-157 effects on tendon, ligament, and gut models (Sikiric et al., 2014). Thymosin beta-4 has a longer scientific history with documented effects on actin sequestration and cell migration (Goldstein et al., 2012). Direct head-to-head or combination studies in humans remain sparse. Most claims about the pairing are theoretical, drawing on overlapping mechanisms rather than on combined clinical evidence.
What to know before considering it
As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Anything purchased outside of a clinical pathway is in the gray-market category, with no quality control, no physician oversight, and no published safety profile.
The Halftime POV
The mechanism story is interesting. The human data is thin. FDA's final decision on each is still pending. That is three different reasons to keep this conversation honest about what is known versus what is hoped for. We track the FDA Federal Register process and will update this post when status changes.
Related reading:
- BPC-157: what this body protection compound is
- TB-500 (thymosin beta-4): what this repair peptide is
- Category 1 vs Category 2 peptides: the access framework
FAQ
Q: Why are BPC-157 and TB-500 often discussed together? A: Both are studied in animal models for tissue repair, and they appear to act on different but complementary pathways — BPC-157 on growth-factor signaling and angiogenesis, TB-500 on cell migration and actin remodeling.
Q: Are BPC-157 and TB-500 FDA-approved? A: No. Neither is FDA-approved for any indication. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Q: Is the human research strong? A: Most BPC-157 and TB-500 research is preclinical — animal and cell-based. Direct human trial data on either compound, and especially on the combination, is limited.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Sikiric P et al., Current Pharmaceutical Design, 2014 — BPC 157 and tissue healing review
- Goldstein AL et al., FEBS Journal, 2012 — Thymosin β4: a multi-functional regenerative peptide
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Why are BPC-157 and TB-500 often discussed together?
Both are studied in animal models for tissue repair, and they appear to act on different but complementary pathways — BPC-157 on growth-factor signaling and angiogenesis, TB-500 on cell migration and actin remodeling.
Are BPC-157 and TB-500 FDA-approved?
No. Neither is FDA-approved for any indication. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Is the human research strong?
Most BPC-157 and TB-500 research is preclinical — animal and cell-based. Direct human trial data on either compound, and especially on the combination, is limited.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.